Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

NEDA-3 Achievement in Early Highly Active Relapsing Remitting Multiple Sclerosis Patients Treated with Ocrelizumab or Natalizumab

Elisabetta Signoriello,Alessio Signori,Giacomo Lus,Giuseppe Romano,Girolama Alessandra Marfia,Doriana Landi, Francesca Napoli,Emanuele D'Amico,Aurora Zanghi, Paola Sofia Di Filippo,Daniele Caliendo,Antonio Carotenuto,Antonio Luca Spiezia,Roberta Fantozzi,Diego Centonze,Matteo Lucchini,Massimiliano Mirabella,Eleonora Cocco,Jessica Frau, Giorgia Teresa Mniscalco,Maria Elena Di Battista,Metteo Foschi,Andrea Surcinelli,Simona Bonavita,Gianmarco Abbadessa,Livia Pasquali,Maria Di Gregorio,Maria Teresa Ferro,Maria Pia Sormani,Irene Schiavetti

Multiple Sclerosis and Related Disorders（2024）

Cited 1|Views23
Key words
Multiple sclerosis,NEDA-3,Ocrelizumab,Natalizumab,Highly active MS patients (HAMS),High-efficacy disease-modifying therapy (HE DMTs)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined